ArticleNeuro-oncology2017

Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.

HuyTram N Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.